Condition
Ovarian Carcinoma, Recurrent clinical trials and research
As of November 12, 2026, Find a Trial lists 2 Ovarian Carcinoma, Recurrent clinical trials that are recruiting, at sites in 2 countries (most in United States (1), South Korea (1)). By phase: Phase 1 (1), Phase 2 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 2Clinical trials
- 2Countries
All recruiting trials (2)
-
Trastuzumab deruxtecan versus standard treatment for ovarian cancer that returned after PARP inhibitor therapy
This study will test whether trastuzumab deruxtecan helps people with HER2-expressing recurrent ovarian, fallopian tube, or peritoneal cancer that progressed on prior PARP inhibitor therapy compared with standard chemotherapy or bevacizumab.
-
CIML NK cell therapy for recurrent ovarian cancer
This study is testing a new treatment using special immune cells to see if it can help people with recurrent high-grade ovarian cancer feel better and improve their health.
Related topics
Quick answers
How many Ovarian Carcinoma, Recurrent clinical trials are recruiting right now?
2, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 2 countries. The most sites are in United States (1 trial), South Korea (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 1: 1, Phase 2: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.